Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 May 1;15(3):314-319.
doi: 10.1097/ICB.0000000000000794.

SHORT-TERM COMPUTER-ASSISTED QUANTIFICATION OF PLUS DISEASE AFTER TREATMENT OF TYPE 1 RETINOPATHY OF PREMATURITY WITH INTRAVITREAL BEVACIZUMAB OR RETINAL LASER PHOTOCOAGULATION

Michelle T Cabrera  1   2 , Thomas Chia  3 , David K Wallace  4 , J Niklas Ulrich  5 , Sharon F Freedman  6   7 , Leona Ding  2 , Kevin R Gertsch  8
Affiliations
Case Reports

SHORT-TERM COMPUTER-ASSISTED QUANTIFICATION OF PLUS DISEASE AFTER TREATMENT OF TYPE 1 RETINOPATHY OF PREMATURITY WITH INTRAVITREAL BEVACIZUMAB OR RETINAL LASER PHOTOCOAGULATION

Michelle T Cabrera et al. Retin Cases Brief Rep. .

Abstract

Purpose: To compare objectively measured changes in plus disease after bevacizumab and laser for Type 1 retinopathy of prematurity.

Methods: ROPtool (a computer program) analyzed fundus images at baseline, 1 week, and subsequent examinations.

Results: Six infants (9 eyes) were treated with bevacizumab and 7 (12 eyes) with laser. One week after treatment, bevacizumab compared with laser resulted in a greater median percent change from pretreatment in tortuosity (-53.8 vs. -0.2%, P < 0.001) and overall plus disease (-20.1 vs. -3.1%, P < 0.001). Change in dilation did not differ (-3.5 vs. -5.5%, P = 0.48). After week 1, all median ROPtool parameters continued to decrease for both groups. At last follow-up (median 3, range: 2-10 weeks), both bevacizumab and laser significantly decreased tortuosity (-54.3 and -23.8%), dilation (-8.7 and -7.5%), and overall plus disease (-27.3 and -10.3%).

Conclusion: Improvement in plus disease, in particular tortuosity, likely occurs more quickly after bevacizumab compared with laser, particularly at 1 week after treatment. These results guide clinical expectations for plus disease resolution after both treatment modalities.

PubMed Disclaimer

References

    1. Wallace DK, Freedman SF, Zhao Z. Evolution of plus disease in retinopathy of prematurity: quantification by ROPtool. Trans Am Ophthalmol Soc 2009;107:47–52.
    1. Kwon JY, Ghodasra DH, Karp KA, et al. Retinal vessel changes after laser treatment for retinopathy of prematurity. J AAPOS 2012;16:350–353.
    1. Johnson KS, Mills MD, Karp KA, Grunwald JE. Quantitative analysis of retinal vessel diameter reduction after photocoagulation treatment for retinopathy of prematurity. Am J Ophthalmol 2007;143:1030–1032.
    1. Cheung CS, Butty Z, Tehrani NN, Lam WC. Computer-assisted image analysis of temporal retinal vessel width and tortuosity in retinopathy of prematurity for the assessment of disease severity and treatment outcome. J AAPOS 2011;15:374–380.
    1. Cabrera MT, Freedman SF, Kiely AE, et al. Combining ROPtool measurements of vascular tortuosity and width to quantify plus disease in retinopathy of prematurity. J AAPOS 2011;15:40–44.

MeSH terms